Dipexium Reports Third Quarter 2016 Financial Results
NEW YORK, Nov. 10, 2016 /PRNewswire/ -- Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX), a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide, today reported financial results for the quarter ended September 30, 2016.
Financial Results for the Third Quarter of 2016
For the three months ended September 30, 2016, Dipexium reported a net loss of $4.6 million, compared to a net loss of $5.0 million for the three months ended September 30, 2015, a decrease of $0.4 million. The change was primarily due to a $0.5 million decrease in manufacturing relating expenses offset by a $0.1 million increase in Phase 3 clinical trial related expenses.
Financial Results for the Third Quarter of 2016
For the three months ended September 30, 2016, Dipexium reported a net loss of $4.6 million, compared to a net loss of $5.0 million for the three months ended September 30, 2015, a decrease of $0.4 million. The change was primarily due to a $0.5 million decrease in manufacturing relating expenses offset by a $0.1 million increase in Phase 3 clinical trial related expenses.